Collaborations, Combos, Immuno-oncology

Bristol-Myers embraces a possible checkpoint collaborator, snagging a batch of stock and lining up a potential deal

Bristol-Myers Squibb $BMY is buddying up with a little biotech that just might have the key to unlocking a checkpoint strategy for one block of cancer patients. 

The big PD-1 player is investing $12 million at a premium price in Compugen, intrigued by early preclinical data that indicate there could be real potential for their checkpoint strategy. That’s not a huge sum, but it’s a clear indication of interest from Bristol-Myers Squibb, which has lined up first rights to negotiating a licensing pact with Compugen.

Compugen’s stock $CGEN surged 10% on the news, with the right to pursue an early-stage study of a combination of Opdivo and COM701.

The little biotech has posted preclinical evidence that suggests elevated levels of the ligand PVRL2 in PD-1 resistant cases may offer a key biomarker for their drug, the PVRIG-targeted COM701. Last summer the FDA lifted a clinical hold it slapped on Compugen’s first-in-human trial for its I/O drug, clearing the Israeli biotech to finally begin its first ever Phase I study.

Peter Welford

Researchers for the company have said that PVRIG and TIGIT, and their respective ligands, “are expressed in a broad variety of tumor types, such as those noted above, as well as lung, kidney, and head & neck cancers.” Ultimately, some patients could require a triple combo targeting PVRIG, TIGIT and PD-1 to achieve a durable response.

Or that’s the theory, anyway. Peter Welford at Jefferies enjoyed reading the news. He noted:

Along with the Phase I study for Bayer-partnered anti-ILDR2 BAY1905254, we could see initial proof-of-concept data over the next 12-24 months, critical to crystallize value.

Bristol-Myers gets a stretch of a few months time to negotiate on a licensing deal as the data emerge. After that, the deal table will be wide open.

Bristol-Myers has been hard at it building their mega blockbuster Opdivo, but fell behind a dominant Merck recently after their Big Pharma rival beat them on frontline lung cancer. Bristol-Myers, though, is a plugger, and they’re not giving up now.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco
Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC

Visit Endpoints Careers ->